StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026Score 9/3079% below fair value
$1.78−0.01 (-0.56%)

Close on Nov 13, 2026Market cap $19.34MP/E –Yield –

Aytu BioPharma gross margin

Gross margin is gross profit as a percentage of revenue.

Aytu BioPharma's gross margin for the twelve months ending Jun 30, 2026 was 64.0%. For fiscal 2026 it was 64.0%, against 69.0% the year before. The highest annual figure on record is 75.3% in fiscal 2024.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2026Jun 30, 202664.0%−5.1
FY2025Jun 30, 202569.0%−6.2
FY2024Jun 30, 202475.3%+13.2
FY2023Jun 30, 202362.0%+8.0
FY2022Jun 30, 202254.1%+9.6
FY2021Jun 30, 202144.5%−25.5
FY2020Jun 30, 202070.0%+0.1
FY2019Jun 30, 201969.9%+25.9
FY2018Jun 30, 201844.0%−12.0
FY2017Jun 30, 201756.0%−6.6
FY2016Jun 30, 201662.6%−3.7
FY2015Jun 30, 201566.3%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q4 FY2026CQ2 2026Jun 30, 202664.6%−3.1
Q3 FY2026CQ1 2026Mar 31, 202661.2%−8.2
Q2 FY2026CQ4 2025Dec 31, 202563.5%−3.0
Q1 FY2026CQ3 2025Sep 30, 202566.1%−6.2
Q4 FY2025CQ2 2025Jun 30, 202567.8%−8.0
Q3 FY2025CQ1 2025Mar 31, 202569.4%−4.5
Q2 FY2025CQ4 2024Dec 31, 202466.5%−11.4
Q1 FY2025CQ3 2024Sep 30, 202472.3%−0.9
Q4 FY2024CQ2 2024Jun 30, 202475.7%+15.3
Q3 FY2024CQ1 2024Mar 31, 202473.9%+17.8
Q2 FY2024CQ4 2023Dec 31, 202377.9%+12.1
Q1 FY2024CQ3 2023Sep 30, 202373.2%+8.0
Q4 FY2023CQ2 2023Jun 30, 202360.4%+6.3
Q3 FY2023CQ1 2023Mar 31, 202356.1%+3.6
Q2 FY2023CQ4 2022Dec 31, 202265.8%+12.6
Q1 FY2023CQ3 2022Sep 30, 202265.2%+8.3
Q4 FY2022CQ2 2022Jun 30, 202254.1%+6.0
Q3 FY2022CQ1 2022Mar 31, 202252.4%+55.8
Q2 FY2022CQ4 2021Dec 31, 202153.2%−5.5
Q1 FY2022CQ3 2021Sep 30, 202156.9%−13.1
Q4 FY2021CQ2 2021Jun 30, 202148.1%−16.2
Q3 FY2021CQ1 2021Mar 31, 2021-3.4%−78.8
Q2 FY2021CQ4 2020Dec 31, 202058.7%−22.2
Q1 FY2021CQ3 2020Sep 30, 202069.9%−4.0
Q4 FY2020CQ2 2020Jun 30, 202064.3%+2.2
Q3 FY2020CQ1 2020Mar 31, 202075.5%+1.4
Q2 FY2020CQ4 2019Dec 31, 201980.9%+10.2
Q1 FY2020CQ3 2019Sep 30, 201973.9%+2.6
Q4 FY2019CQ2 2019Jun 30, 201962.2%−11.8
Q3 FY2019CQ1 2019Mar 31, 201974.1%+161.2
Q2 FY2019CQ4 2018Dec 31, 201870.7%+7.4
Q1 FY2019CQ3 2018Sep 30, 201871.3%−2.0
Q4 FY2018CQ2 2018Jun 30, 201873.9%+15.8
Q3 FY2018CQ1 2018Mar 31, 2018-87.1%−150.8
Q2 FY2018CQ4 2017Dec 31, 201763.3%+32.8
Q1 FY2018CQ3 2017Sep 30, 201773.3%+0.8
Q4 FY2017CQ2 2017Jun 30, 201758.2%–
Q3 FY2017CQ1 2017Mar 31, 201763.7%–
Q2 FY2017CQ4 2016Dec 31, 201630.6%–
Q1 FY2017CQ3 2016Sep 30, 201672.5%–

More Aytu BioPharma figures

See a number that looks wrong?